Biogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
|
|
- Baldric Shepherd
- 6 years ago
- Views:
Transcription
1 Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009
2 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Market AVONEX TYSABRI BG12 Anti-CD20 Daclizumab CDP323 PEG-IFN β-1a Anti-LINGO-1 Selective S1P agonist Current Pipeline Progress Goals Neurology Other Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Market A2a antagonist (BIIB014) Neublastin Parkinson s Neuropathic Pain 2
3 R&D Leadership in MS Working to fulfill unmet needs More convenient therapies: BG12 More effective therapies: anti-cd20 CDP323 CDP323 PEG-IFNβ Daclizumab S1P1 agonist S1P1 agonist Inhibit neurodegeneration/enhance repair: BG12 anti-lingo Silence Inflammation Protect nerve cells Repair the damage 3
4 The Two Sides of MS Pathophysiology Time since disease onset Inflammation (interferon-sensitive) conduction block, demyelination, bystander axonal injury Relapsing- Remitting Degeneration (interferon-resistant) loss of neurons/axons Secondary Progressive 4
5 BG12 Molecule Formulation Second generation fumaric acid (Dimethyl fumarate) Enteric-coated microtablet Molecular Hypothesis Anti-inflammatory effects Cytoprotective effects Note: BIIB acquired Fumapharm AG 5
6 The Nrf2 Pathway The Key to Neuroprotection in MS? Keap1 Nrf2 X Nrf2 Nrf2 Maf Jun ATF4 - Detox Enzymes - Antioxidant Enzymes - NADPH Generating Enzymes - GSH Biosynthesis Enzymes - Chaperones - Ubiquitination/Proteasome ARE Nucleus - Detoxification - Normalization of energy metabolism - Repair/degradation of damaged proteins 6
7 BG12 Activates the Nrf2 Pathway O O O O BG-12 Keap1 Nrf2 Nrf2 Maf Jun ATF4 - Detox Enzymes - Antioxidant Enzymes - NADPH Generating Enzymes - GSH Biosynthesis Enzymes - Chaperones - Ubiquitination/Proteasome Keap1 ARE Nucleus - Detoxification - Normalization of energy metabolism - Repair/degradation of damaged proteins 7
8 The Nrf2 Pathway Appears to be Important in Maintaining CNS Myelin 8
9 Nrf2 Induces a Cytoprotective Response and Inhibits Inflammatory Events Nrf2 Detoxification enzymes Antioxidant enzymes NADPH-generating enzymes GSH biosynthesis enzymes Chaperones Ubiquitination / proteasome Decreases Proinflammatory cytokines Leukocyte adhesion molecules Lymphocyte activation CYTOPROTECTION INFLAMMATION AND TISSUE DAMAGE 9
10 BG12 Phase 2b Study in RRMS 10
11 BG12 Phase 2b Study Results - Primary Endpoint 11
12 Evidence of Neuroprotection in MS? BG12 Reduced Conversion of New Gd+ Lesions to T1 Hypointense Lesions (100%) 200 OR for conversion = 0.51 (95% CI = 0.43, 0.61) P Total No. of Lesions (44%) 147 (100%) (29%) 0 Gd+ lesions (Week 4-12) T1 lesions (Week 24) Gd+ lesions (Week 4-12) T1 lesions (Week 24) Placebo 12 BG mg tid
13 BG12 Phase 2b Study Results - Safety 13
14 Excerpt from Accompanying Editorial in The Lancet The balance between efficacy, safety, and convenience will be decisive for the choice of drug. Oral formulations have advantages in convenience and will be preferred by most patients, as long as efficacy and safety are similar to that of injectable alternatives. Although comparison of drugs tested in different placebo-controlled trials is difficult and should be done cautiously, BG00012 might have a favourable benefit-to-risk profile compared with its oral competitors and the currently available first-line injectable drugs. However, we will have to await the results from the ongoing large phase III trials to establish the place of BG00012 and other oral drugs in the treatment of relapsing-remitting multiple sclerosis. Copenhagen, Denmark --- Per Soelberg Sorensen and Finn Sellebjerg, Danish Multiple Sclerosis Research Center, 14
15 BG12 Summary IFN-like efficacy on new inflammatory lesions in RRMS Mechanism of action suggests potential for additional neuroprotective effects FUMADERM : 15-year track record of long-term safety of dimethyl fumarate Two multicenter, parallel-group, randomized, placebo-controlled, dose-comparison, phase 3 clinical studies being conducted 2 doses of BG-12 (240mg bid and 240mg tid) and placebo; 1011 pts Primary endpoint: Proportion of patients relapsing over two years Fully enrolled in Q doses of BG-12, glatiramer acetate and placebo; 1232 pts Primary endpoint: Annualized relapse rate at two years Completion of enrollment expected in mid
16 PEGylated Interferon β-1a (PEG IFN) Molecule PEGylated Interferon Beta-1a Mode of Administration Subcutaneous q2 or q4 weeks Molecular Hypothesis Similar efficacy and tolerability to interferon β Reduce the frequency of administration so as to improve convenience and compliance 16
17 PEG IFN Structure PEGylated version of Inteferon β-1a delivered via liquid prefilled syringe Modified at the N-terminal α-amino group Increased half-life and systemic exposure of the protein May improve convenience and compliance for patients with MS who use Interferons PEGylated Interferon Beta-1a molecule, structural representation 17
18 PK/PD Characteristics of PEG IFN Antiviral Activity (U/mL) Median Antiviral Activity by Treatment Groups Time (h) Avonex, IM, 30 mcg BIIB017, SC, 63 mcg BIIB017, SC, 125 mcg BIIB017, SC, 188 mcg Neopterin Concentration (ng/ml) Median Neopterin Concentration by Treatment Groups Avonex, IM, 30 mcg BIIB017, SC, 63 mcg BIIB017, SC, 125 mcg BIIB017, SC, 188 mcg Time (h) Higher exposures and longer half-life than Avonex Higher and more sustained elevations in neopterin than Avonex However, flu-like symptoms and other side effects were comparable to Avonex at doses up to 125 mcg SC 18
19 PEG IFN Phase 3 Study Design Screening Year 1 Year 2 Follow-up Randomization PLACEBO BIIB mcg SC, Q2W BIIB mcg SC, Q4W N = 420 ~1260 patients (naïve to IFN) BIIB mcg SC, Q2W BIIB mcg SC, Q4W N = 420 N = 420 Titration 1 yr Superiority 2 yr Safety/ Immuno 19
20 PEG IFN Conclusions Encouraging results from Phase 1 studies Milestones to date on or ahead of schedule Positive Agency feedback on the Phase 3 plans Realistic but aggressive plan going forward to approval 20
21 Multiple Approaches to MS Therapeutics Anti-CD20 Selective S1P1 agonist BG00012 Natalizumab/ CDP 323 Daclizumab IFNβ-1a, PEG-IFN β-1a IFNβ-1a, PEG-IFN β-1a Anti-LINGO-1 21
22 Neurology Pipeline Conclusions Robust neurology pipeline Leadership in MS Targeted expansion into non-ms diseases 22
23 Biogen Idec Research & Development Day March 25, 2009
Aubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018
Aubagio (teriflunomide tablets) Policy Number: 5.01.614 Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationThere are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationDimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials
Dimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore, Maryland Abstract Treatment options for multiple
More informationClinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Utility of Glatiramer Acetate in the Management
More informationTysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab
PHARMACOVIGILANCE AND REGISTRY PROGRAMMES Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab Eric Van Ganse Pharmacoepidemiology, CHU-Lyon France OUTLINE I. GOOD REGISTRY PRACTICE
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationTITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE
TITLE OF PRESENTATION SECOND QUARTER 2014 FINANCIAL RESULTS & BUSINESS UPDATE JULY 23, 2014 Forward-Looking Statements This presentation contains forward-looking statements, including statements about
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationThe Latest Innovations in the Drug Pipeline for Multiple Sclerosis
CLINICAL SPECIAL FEATURE The Latest Innovations in the Drug Pipeline for Multiple Sclerosis Lea Radick and Stanton R. Mehr Am Health Drug Benefits. 2015;8(8):448-453 www.ahdbonline.com Disclosures are
More informationTiming is Everything: The Importance of Early Intervention in Multiple Sclerosis
Timing is Everything: The Importance of Early Intervention in Multiple Sclerosis Challenge Question: Pathophysiology Which of the following is a correct statement about the pathophysiology of MS and/or
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab),
More informationAdvances in Immunomodulatory Therapy for Multiple Sclerosis
Advances in Immunomodulatory Therapy for Multiple Sclerosis Sona Narula, MD Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Abstract Significant research has been directed toward the development
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationA Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis
Original Article J Clin Med Res. 2018;10(2):88-105 A Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis Vida Hamidi a, Elisabeth Couto a, Tove Ringerike a, Marianne
More informationGuideline on similar biological medicinal products containing interferon beta
1 2 3 15 December 2011 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on similar biological medicinal products containing interferon beta 7 Draft Draft
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0023P Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report October 2014 Drug Teriflunomide (Aubagio) (14 mg film-coated tablet) Indication Teriflunomide is indicated as monotherapy for the treatment of patients
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationPATIENT GROUPS & CLINICAL TRIALS CASE STUDY
February 1, 2017 PATIENT GROUPS & CLINICAL TRIALS CASE STUDY Jeffrey W. Sherman, M.D., FACP Past President Inaugural Fellow Chief Medical Officer Executive Vice President Disclaimer The views and opinions
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationThe Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan
The Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan October 7, 2016 Prepared for Institute for Clinical and Economic Review,
More informationA BS TR AC T. n engl j med 367;12 nejm.org september 20,
The new england journal of medicine established in 1812 september 20, 2012 vol. 367 no. 12 -Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis Robert J. Fox, M.D., David H. Miller,
More informationQuantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology Michael G Tovey, Director, Laboratory of Viral Oncology, Institut André Lwoff, Villejuif,
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAVONEX (Interferon beta-1a) IM Injection DESCRIPTION
AVONEX (Interferon beta-1a) IM Injection DESCRIPTION AVONEX (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant
More informationCredit Suisse 7 th Annual European Large Cap Pharmaceutical Conference. November 6, 2007
Credit Suisse 7 th Annual European Large Cap Pharmaceutical Conference November 6, 2007 Safe Harbor Statement This presentation contains forward-looking statements about Elan s financial condition, results
More informationEmerging Therapies for the Management of Multiple Sclerosis
Clinical Medicine Insights: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Emerging Therapies for the Management of Multiple Sclerosis
More informationThe Economics of New Drug Development: Costs, Risks, and Returns
The Economics of New Drug Development: Costs, Risks, and Returns Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting
More informationDeveloping Therapeutics for the Treatment of Multiple Sclerosis
NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics Developing Therapeutics for the Treatment of Multiple Sclerosis David J. Virley Neurology and GI Centre of Excellence for
More informationISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45
ISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45 Introduction Alastair Kent, OBE, Genetic Alliance UK, London, UK Recent HTA decisions Jacco Keja, PhD, IMS Health, Rotterdam, The Netherlands
More informationTechnology Overview. 1. Background of Technology. (1) Regulatory Status
Apimeds, Inc. 1 Technology Overview 1. Background of Technology (1) Regulatory Status - New Drug Approval of KFDA (The 6th New Drugs in Korea, The first natural biological drug of its kind). The animal
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
FOR IMMEDIATE RELEASE December 21, 2017 Eisai Co., Ltd. Biogen Inc. ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT CRITERIA FOR SUCCESS AT 12-MONTH ANALYSIS
More informationReview of week-24 results
Review of week-24 results GNC-003: an international, double-blind, randomized, placebo-controlled phase IIb trial to assess the efficacy, safety and pharmacokinetics of in patients with relapsing remitting
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationSamatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination
More informationACTELION TRANSFORMATION ON THE WAY. Jean-Paul Clozel Chief Executive Officer. Copyright 2016 Actelion Pharmaceuticals Ltd
ACTELION 2015 2020 TRANSFORMATION ON THE WAY Jean-Paul Clozel Chief Executive Officer Copyright The following information contains certain forward-looking statements, relating to the company s business,
More informationFORMULARY MANAGEMENT ABSTRACT
FORMULARY MANAGEMENT Pharmacy Benefit Forecast for a New Interferon Beta-1a for the Treatment of Multiple Sclerosis: Development of a First-Line Decision Tool for Pharmacy-Budget Planning Using Administrative
More informationAdherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
ORIGINAL RESEARCH Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience Tatiana de Melo Gomes de Oliveira 1 Ana Patricia Peres Fiore 2 Yára Dadalti Fragoso 2 1 TEVA
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationPhase 1 Clinical Studies First-In-Human (FIH) <Chapter 31> Pharmacologically-Guided Dose Escalation
Phase 1 Clinical Studies First-In-Human (FIH) Pharmacologically-Guided Dose Escalation Jerry M. Collins, Ph.D. Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis,
More informationDIFFERENTIATION WITHOUT DISRUPTION
DIFFERENTIATION WITHOUT DISRUPTION In this article, Alan Shortall, Chief Executive Officer, Unilife Corporation, describes a new paradigm now driving the pharmaceutical market for advanced drug delivery
More informationME-401: A Highly Differentiated PI3Kd- Selective Inhibitor
NASDAQ: MEIP ME-401: A Highly Differentiated PI3Kd- Selective Inhibitor June 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual
More informationTo Our Shareholders: Reaching Patients with PNH and ahus
To Our Shareholders: In 2014, Alexion continued to expand its commercial and clinical operations as we advanced our mission to develop and deliver life-transforming therapies for patients with severe and
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationRP-HPLC METHOD FOR QUANTITATIVE ESTIMATION OF GLATIRAMER ACETATE FOR INJECTION IN PHARMACEUTICAL DOSAGE FORMS
RP-HPLC METHOD FOR QUANTITATIVE ESTIMATION OF GLATIRAMER ACETATE FOR INJECTION IN PHARMACEUTICAL DOSAGE FORMS ABSTRACT A simple RP-HPLC method for the determination of Glatiramer acetate in pharmaceutical
More informationREVIEW ARTICLE. Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis. (MS) is a multifocal, demyelinating disease
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis A Systematic Review REVIEW ARTICLE Steven L. Galetta, MD; Clyde Markowitz, MD; Andrew G. Lee, MD Background: Within the past 10
More informationIntec. Pharma Unfolding drug delivery solutions. Investor Presentation. Nasdaq: NTEC. June 2017
Intec Pharma Unfolding drug delivery solutions Investor Presentation Nasdaq: NTEC June 2017 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as we or our ) contains forward-looking
More informationJefferies Healthcare Conference
0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor
More informationReview of Phase IIb week-24 results
The leader in the treatment of HERV-mediated diseases Review of Phase IIb week-24 results As presented at MS Paris 2017 October 30, 2017 www.geneuro.com Disclaimer This presentation has been prepared by
More informationPreclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator
S830 Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator Yue Chen, Raj Nagaraja, Kha Le, Penelope A Kosinski, Gavin Histen, Charles Kung, Hyeryun Kim, Chandra
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationCurrent and Emerging Therapies in Multiple Sclerosis: A Systematic Review
University of Connecticut DigitalCommons@UConn Articles - Research University of Connecticut Health Center Research 7-2012 Current and Emerging Therapies in Multiple Sclerosis: A Systematic Review Wanda
More informationRoche Committed to Innovation. Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008
Roche Committed to Innovation Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008 This presentation contains certain forward-looking statements. These forward-looking statements
More informationA look into the future - International Progressive MS Alliance. Dr Dhia Chandraratna Head of Research, MSIF
A look into the future - International Progressive MS Alliance Dr Dhia Chandraratna Head of Research, MSIF Neurologist: Accumulation of disability Gradual change over time Imager: Defining Progressive
More informationNEUROLOGY AND OPHTHALMOLOGY
NEUROLOGY AND OPHTHALMOLOGY OPPORTUNITIES AT INSERM BD & L: Anne Cochi anne.cochi@inserm-transfert.fr September 2017 1 WE PROPOSE A SELECTION OF PROJECTS AT DIFFERENT STAGES 4 Neurodegeneration patents
More informationDrug Development in Inflammatory Bowel Disease: The FDA Perspective
Drug Development in Inflammatory Bowel Disease: The FDA Perspective Kerry Jo Lee, M.D. Division of Gastroenterology and Inborn Errors Products U.S. Food and Drug Administration 1 Disclosure Kerry Jo Lee,
More informationHEALTH TECHNOLOGY ASSESSMENT
HEALTH TECHNOLOGY ASSESSMENT VOLUME 21 ISSUE 52 SEPTEMBER 2017 ISSN 1366-5278 Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic
More informationFirst Quarter Financial Results and Business Update
First Quarter 2018 Financial Results and Business Update April 24, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: our strategy
More informationEmerging Medical Therapies in Inflammatory Bowel Disease
Emerging Medical Therapies in Inflammatory Bowel Disease - 2017 Nir Modiano, MD, PhD Assistant Professor of Medicine Division of Gastroenterology & Hepatology Director, Inflammatory Bowel Disease Program
More informationCorporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationEvidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal
Evidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal Title: Fingolimod for the treatment of relapsing remitting
More informationWe are committed to translating ground-breaking science into genomic therapies that transform patients lives
We are committed to translating ground-breaking science into genomic therapies that transform patients lives Liver-based expression of the human alpha-galactosidase A gene (GLA) in a murine Fabry model
More informationThe quality of reports of randomized trials in multiple sclerosis: a review
444327MSJ18610.1177/1352458512444327Signori et al.multiple Sclerosis Journal 2012 Topical Review MULTIPLE SCLEROSIS JOURNAL MSJ The quality of reports of randomized trials in multiple sclerosis: a review
More informationTITLE: Novel Small-Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus
AWARD NUMBER: W81XWH-16-1-0609 TITLE: Novel Small-Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus PRINCIPAL INVESTIGATOR: Abhishek Trigunaite CONTRACTING ORGANIZATION: SRI International
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationjournal of medicine The new england A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Abstract
The new england journal of medicine established in 1812 march 2, 2006 vol. 354 no. 9 A Randomized, -Controlled Trial of for Relapsing Multiple Sclerosis Chris H. Polman, M.D., Paul W. O Connor, M.D., Eva
More informationMapi Pharma Value-Added High-Barrier to Entry Pharmaceuticals Q4 2014
Mapi Pharma Value-Added High-Barrier to Entry Pharmaceuticals Q4 2014 1 Corporate Overview Strategy Growth Engines Building a vertically integrated, diversified, risk mitigated business model with high-barrier,
More informationInjection Guide for Treatment with the AVONEX Prefilled Syringe
For people with relapsing forms of multiple sclerosis (MS) Injection Guide for Treatment with the AVONEX Prefilled Syringe For important safety information, please see pages 13-15 and the enclosed full
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationAdvancing New Treatments for DMD and C. difficile Infection
Advancing New Treatments for DMD and C. difficile Infection 34 th Annual Canaccord Genuity Growth Conference August 13, 2014 Legal Disclaimer FORWARD-LOOKING STATEMENTS This Document contains forward-looking
More informationPrior Authorization Form
5/2/2017 Prior Authorization Form INTOTAL HEALTH PLAN (SPC) Multiple Sclerosis MMT SGM This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationBIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation
More informationRebiotix: Business, Regulatory and Clinical Challenges in Commercializing a Microbiota Based Drug. May 2016
Rebiotix: Business, Regulatory and Clinical Challenges in Commercializing a Microbiota Based Drug May 2016 Rebiotix Pioneer in Microbiome Therapeutics Privately held clinical stage biotechnology company
More informationPRODUCT INFORMATION. AVONEX is produced by recombinant DNA technology and is manufactured as a 30 microgram powder or solution for injection.
PRODUCT INFORMATION AVONEX interferon beta-1a (rch) Powder for Injection and Solution for Injection NAME OF THE MEDICINE Interferon beta-1a is a 166 amino acid glycoprotein with a specific activity of
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationThe Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis
The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland
More informationREFCTRI/2010/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 18 Feb 2018 17:17:30 GMT) CTRI Number CTRI/2010/091/000254 [Registered on: 09/09/2010] - Last Modified On 05/03/2013 Post Graduate Thesis Type of Trial
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationIdenix Pharmaceuticals: Building a Leading Antiviral Franchise. Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Spring 2005
Idenix Pharmaceuticals: Building a Leading Antiviral Franchise Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Spring 2005 Safe Harbor This presentation includes forward-looking statements about Idenix
More informationSwissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
More informationDeveloping T cell vaccines for HSV-2 Infection
Developing T cell vaccines for HSV-2 Infection Jessica Baker Flechtner, PhD World Vaccine Congress 24-26 March, 2014 Deep Pipeline of T Cell-Enabled Vaccine Candidates Discovery Pre-clinical Phase 1 Phase
More information90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Exhibit 19: Key Psoriasis Clinical Trials (Phase 3) Data compiled not from head-to-head studies Exhibit 20: Long-Term Response PASI-90 and PASI-100 (Phase 3) Data compiled not from head-to-head studies.
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationDirucotide (MBP8298) for the treatment of multiple sclerosis
DRUG EVALUATION Dirucotide (MBP8298) for the treatment of multiple sclerosis Clyde Markowitz University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA Tel.: +1
More information